P04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infection

DSpace/Manakin Repository

P04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infection

Show simple item record

dc.contributor.author Mikell, I
dc.contributor.author Sather, D
dc.contributor.author Kalams, S
dc.contributor.author Stamatatos, L
dc.contributor.author Altfeld, Marcus
dc.date.accessioned 2011-03-25T16:14:29Z
dc.date.issued 2009
dc.identifier.citation Mikell, I., D. Sather, S. Kalams, Marcus Altfeld, and L. Stamatatos. 2009. P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection. Retrovirology 6(Suppl 3): P43. en_US
dc.identifier.issn 1742-4690 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4774089
dc.description.abstract Background: Determining how cross-reactive neutralizing antibody (NAb) responses develop during natural HIV-1 infection may provide key information to understand the role they play in controlling the infection and in disease progression. Here we investigated the frequency and breadth of broadly NAb responses during acute and early infection in a well controlled cohort, and attempted to characterize the factors associated with the development of such responses. Methods: The plasma of 38 clade B acutely-infected, antiretroviral-naive subjects from two cohorts was screened for breadth of neutralization against a panel of heterologous isolates in an Env pseudovirus neutralization assay. Clade A, B and C variants were chosen from reference panels of viruses, created to evaluate the NAb responses elicited during infection or immunization. Results: Our preliminary screening strategy demonstrated that broadly neutralizing antibodies can be detected in a third of the infected subjects. Breadth of neutralization can develop as early as one year during natural HIV infection, however the majority of breadth was observed at over two years post infection. Conclusion: Cross-reactive NAbs are developed more frequently during early infection than previously thought. The consequences of this 'early' development of cross-reactive NAbs on plasma viremia and disease progression are under investigation. The work described was supported by National Institute of Health grant number R01 AI047708-11. en_US
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.relation.isversionof doi:10.1186/1742-4690-6-S3-P43 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767944/pdf/ en_US
dash.license LAA
dc.title P04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infection en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Retrovirology en_US
dash.depositing.author Altfeld, Marcus
dc.date.available 2011-03-25T16:14:29Z
dash.affiliation.other HMS^Medicine-Massachusetts General Hospital en_US

Files in this item

Files Size Format View
2767944.pdf 128.8Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters